Pulmonology
Lungs & breathing clinical trials
Asthma, COPD, and other conditions that affect the lungs and breathing. We’re tracking 6,352 recruiting studies in this area right now.
By phase
- Not applicable4,048
- Phase 2834
- Phase 1460
- Phase 3421
- Phase 1/Phase 2312
- Phase 4213
- Phase 2/Phase 364
Top conditions
- Lung Cancer416
- Asthma194
- Non-Small Cell Lung Cancer182
- Non Small Cell Lung Cancer178
- Non-small Cell Lung Cancer157
- Obstructive Sleep Apnea142
- COPD134
- Breast Cancer111
- Pulmonary Hypertension105
- Colorectal Cancer89
- COVID-1988
- NSCLC87
- Chronic Obstructive Pulmonary Disease84
- Chronic Obstructive Pulmonary Disease (COPD)78
- Cystic Fibrosis77
- Interstitial Lung Disease75
- Ovarian Cancer71
- Pneumonia68
Leading sponsors
- Assistance Publique - Hôpitaux de Paris73
- AstraZeneca65
- Mayo Clinic52
- M.D. Anderson Cancer Center45
- National Cancer Institute (NCI)42
- VA Office of Research and Development40
- Shanghai Chest Hospital35
- Memorial Sloan Kettering Cancer Center33
- University Health Network, Toronto33
- GlaxoSmithKline30
Where studies are running
- California385
- Alabama175
- Arizona154
- Florida121
- Massachusetts118
- Maryland115
- New York111
- Texas87
- Pennsylvania82
- Illinois73
Recruiting studies6,352 total
- NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT07023068Enrolling by invitationEarly Phase 1
68Ga-DPA scan for lung cancer diagnosis
This trial tests a new imaging agent called 68Ga-DPA to see if it can help find and measure lung cancer tumors. It is for people who are suspected or confirmed to have lung cancer and need a biopsy or surgery soon.
BeijingAges 18–85 - NCT04183660Recruiting
MOBYBOX monitoring study for temporary heart-lung support
This is a post-market “real-world” monitoring study for a heart-lung machine (extracorporeal cardiopulmonary support/ECMO) used during very serious heart and/or lung failure. It aims to track safety and performance in patients who need rescue breathing or circulation support.
Hanover, Lower SaxonyAges 18–80 - NCT04664491Recruiting
Program to reduce COPD flare-ups with standardized care
This study tests whether a structured care program for COPD can lower how often your symptoms flare up. It may help by improving everyday management and preventing future worsening.
Beijing, Beijing MunicipalityAges 40 years+ - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT06350032RecruitingPhase 3
Testing treprostinil safety in children with PAH
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
Vienna, State of ViennaAges Up to 18 years - NCT07012031RecruitingPhase 1/Phase 2
Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer
This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07011524RecruitingPhase 2
Study of CM512 injection for moderate-to-severe asthma
This trial tests a new injection, CM512, for people with moderate-to-severe asthma that is not well controlled with current inhalers. It aims to see if the treatment can reduce asthma attacks and improve symptom control.
Guangzhou, GuangdongAges 18–75 - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07010419RecruitingPhase 3
Firmonertinib vs placebo for early-stage lung cancer with rare EGFR mutations
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07008287Recruiting
Taletrectinib for ROS1+ lung cancer with brain spread
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hangzhou, ZhejiangAges 18 years+ - NCT07003321RecruitingPhase 2
Testing HRS-4508 for advanced non-small cell lung cancer
This trial tests an experimental drug called HRS-4508 for people with advanced non-small cell lung cancer that has stopped responding to standard treatments or cannot tolerate them. The goal is to see if it can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Iowa City, IowaAges 18–100 - NCT07013474RecruitingPhase 3
Study of ibuzatrelvir for immunocompromised adults with COVID-19
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
Canoga Park, CaliforniaAges 18 years+ - NCT07012304RecruitingPhase 1/Phase 2
Testing gecacitinib for chronic graft-versus-host disease after 2 or more treatments
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
BeijingAges 18 years+ - NCT07004946Recruiting
New microscope probe for lung lesion diagnosis
This study tests a new microscope probe called CelTouch that doctors can use during a lung biopsy to see cells in real time, which may help diagnose lung lesions more accurately.
Guangzhou, GuangdongAges 18–80 - NCT07012759Recruiting
Study of fluid markers in lung adenocarcinoma
This study is looking at certain substances in the fluid around the lungs (pleural effusion) of people with lung adenocarcinoma. It may help doctors understand this condition better and find new ways to treat it.
New Taipei CityAges 18 years+ - NCT07011433Enrolling by invitation
Pneumonia germs, inflammation, and recovery
This study looks at how certain parts of the bacteria that cause pneumonia (called virulence factors) and your body's natural inflammation markers are related to how well you recover. The goal is to learn more about what affects pneumonia outcomes, which could help doctors personalize treatment.
KaunasAges 18 years+ - NCT07009509Recruiting
Yes-Can! program to prevent youth vaping
This study tests a program called YES-CAN! that aims to keep middle and high school students from starting to vape nicotine. If you are a student in grades 6-12, or an adult working in a school, you may be able to join.
Aurora, ColoradoAges 9 years+ - NCT07011810RecruitingPhase 2
Axatilimab for sclerotic chronic graft-versus-host disease
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Tampa, FloridaAges 18 years+ - NCT07012772RecruitingPhase 2
Testing a new airway device for sedated ERCP
This trial tests a new breathing device (called a combo endoscopy oropharyngeal airway) to help keep your airway open during a sedated ERCP procedure. It may improve safety and comfort for people having this exam.
Hangzhou, ZhejiangAges 18 years+ - NCT07003646Recruiting
Treating acute pulmonary embolism with clot-dissolving or catheter procedures
This study looks at how well different treatments work for a blood clot in the lung (pulmonary embolism). It includes people who are getting or have already gotten a clot-dissolving medicine or a catheter procedure to remove the clot.
AarhusAges 18 years+ - NCT07003399Recruiting
Breathing Muscle Function in Sleep Apnea and COPD
This study looks at how the diaphragm (the main breathing muscle) and the drive to breathe work in people with sleep apnea, COPD, or both. Researchers want to compare these groups with healthy volunteers to better understand breathing problems.
Nanjing, JiangsuAges 18–80 - NCT07008664Recruiting
DNA test for lung cancer diagnosis
This study is testing a new blood test to help diagnose lung cancer by looking at certain markers in your DNA. Researchers want to see if this test can accurately find lung cancer, which could lead to earlier detection.
Glen Burnie, MarylandAges 18 years+
Common questions
- How many lungs & breathing clinical trials are recruiting?
- Clin2 is tracking 6,352 recruiting pulmonology studies from the U.S. registry right now, out of 10,005 we cover in this area in total.
- What does “Lungs & breathing” cover here?
- Asthma, COPD, and other conditions that affect the lungs and breathing. We group each study into lungs & breathing based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a lungs & breathing trial near me?
- Use the search to filter lungs & breathing studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.